Hanmi Pharmaceutical's 3.2 Trillion Won Technology Transfer Boosts Biotech Sector Amid Samsung Electronics' Plunge

Despite Samsung Electronics' intraday plunge of 9%, the market remained relatively calm without a circuit breaker or sell-side activation. This suggests that, unlike in the past, the impact of a sharp drop in a specific stock on the overall market has decreased. As the concentration of supply and demand in the semiconductor sector eases, a trend of funds being dispersed into various individual sectors is observed.

Hanmi Pharmaceutical announced this morning a massive technology transfer agreement worth 3.2 trillion won with Genentech, a subsidiary of Roche. This is the largest agreement for a single substance, demonstrating global big pharma's significant interest in the obesity treatment market. This technology transfer is expected to be a crucial turning point in restoring investor sentiment across the entire biotech sector. Consequently, positive evaluations and the potential for additional investment inflows into domestic biotech companies are increasing.

Former President Trump has shifted his approach to Iran, opting for strong economic sanctions instead of military pressure. This is interpreted as a strategy to completely block Iran's oil trade and bring Iran back to the negotiating table through the largest organized economic isolation operation in history. If China also joins these sanctions, it is observed that Iran will no longer be able to resist and will eventually have to enter negotiations.

Currently, there is a perspective that SK Hynix has higher investment attractiveness than Samsung Electronics. SK Hynix is raising expectations for shareholder returns by announcing share buybacks and cancellations, and major events such as the groundbreaking ceremony for its advanced packaging plant in Indiana, USA, are imminent. Furthermore, its cooperation with Nvidia allows for sustained growth as a major beneficiary of memory bottleneck issues, which is a positive factor.

The current semiconductor market has become more challenging for investors due to intensifying differentiation among stocks. It is no longer a market where all semiconductor-related stocks rise together when Samsung Electronics rises, or all fall together when Samsung Electronics declines. There is an opinion that companies with 독점적 technological capabilities remain valid buys even during corrections, and market expectations for Nvidia's earnings announcement are very high.

TSE, a semiconductor inspection equipment company, showed a strong rebound of nearly 13% intraday and 11% at closing, despite Samsung Electronics' sharp decline. This is thanks to TSE's 독점적 technological capabilities, which cover all areas including probe cards, interface boards, and sockets. It is demonstrating the fastest recovery resilience within the materials, parts, and equipment (SobuJang) sector, attracting strong market attention.

Expectations for the U.S. virtual asset market are rising as the CLARITY Act approaches a Senate vote on September 15. With one-fifth of American adults invested in virtual assets, analysis suggests that former President Trump will inevitably introduce strong virtual asset-related policies ahead of the midterm elections. This is expected to further strengthen Bitcoin's status as 'digital gold'.

Naver is garnering attention as a company expected to show strong price surges after AI performance verification. Naver's stability, reflecting polymarket probabilities, is highlighted regardless of the stablecoin approval failure. Furthermore, the increase in equity value due to investment in Anthropic is also expected to positively impact Naver's stock price.

SK Telecom is expected to see its equity value re-evaluated due to the rise in Anthropic's corporate value, and it is a key company responsible for AI infrastructure and cloud business within the SK Group. Through its cooperation network with major global AI companies such as Nvidia, OpenAI, and Palantir, it is considered the most direct investment company in the artificial intelligence sector. This diversified pursuit of AI-related businesses will serve as SK Telecom's future growth engine.

Hanmi Pharmaceutical licensed out its HM17321 substance to Genentech, a subsidiary of the Roche Group, for 3.2 trillion won. This is the largest technology transfer case for a single substance, reflecting high expectations for a next-generation obesity treatment that simultaneously achieves weight loss and muscle preservation. This agreement is a significant achievement that proves Hanmi Pharmaceutical's technological prowess and the potential of its obesity treatment pipeline in the global market.

The obesity treatment market is projected to reach 200 trillion won and is evaluated as a field with continuous, rather than one-time, demand. As the global obese population increases, competition for obesity treatment technology among global pharmaceutical companies is intensifying. This market environment is expected to provide long-term growth drivers for related companies.

Ildong Pharmaceutical is regarded as a top-tier domestic company in the low-molecule oral obesity treatment market. The company has secured relatively good safety and clinical data, giving it a competitive edge. With its stock price having fallen to one-third of its peak, expectations are barely reflected, making its future rebound potential noteworthy.

ST Pharm is identified as a leading stock related to mRNA. ST Pharm, a supplier of oligonucleotide raw materials for mRNA, is considered a practical beneficiary. It is also expected to receive the biggest indirect benefit if the Biosecurity Act passes, and currently, its attractive price and increasing CDMO (Contract Development and Manufacturing Organization) contracts lead to a positive outlook.

Tesla has officially announced the launch event for its robotaxi on September 3. Already, 8,000 robotaxis have been approved in Nevada, and pilot operations are scheduled to begin in Texas. Tesla claims its autonomous driving technology has entered Level 4-5, which is expected to be a new turning point for the autonomous driving market.

For LGCS investment strategy, a plan has been proposed to confirm the passage of the stablecoin vote after the September 15 voting date and then decide whether to buy. This is an approach to minimize risk by entering after resolving uncertainties. MooGiToo and HanTooo were recommended as short-term trading stocks.

Despite a 40% decline in the July market, the importance of portfolio stability was emphasized, citing Warren Buffett's 'selective concentration' investment theory. It was explained that the principle of not putting all your eggs in one basket does not simply mean dividing all stocks equally, but rather concentrating on key sectors to maximize profits. It was stressed that a strategy of focusing on key sectors, considering market conditions and stock-specific characteristics, is more important than stock diversification. Managing an account merely to boast about profits was criticized as meaningless, and prudent portfolio management was urged.